ATLANTA, September 29, 2014 – NeurOp, Inc. announced today that the National Institutes of Health (NIH) has awarded it a grant to support research on new Alzheimer’s disease treatments. NeurOp is investigating subunit-selective N-methyl D-aspartate (NMDA) receptor compounds as potential therapeutics. The grant is a one-year award and will be conducted in collaboration with Dr. Jon Johnson at the University of Pittsburgh.
“Alzheimer’s disease has devastating effects on patients and their families,” said Barney Koszalka, Ph.D., NeurOp president and CEO. “Our research suggests that targeting specific subunits of NMDA receptors may lead to a new generation of drugs that may enhance cognitive performance, as well as impact the progression of other diseases of the central nervous system. This is the third grant we’ve received from the NIH to fund research based on our NMDA receptor modulation platform, and we look forward to further exploring the potential it has for patients.”
This project is supported by the National Institute on Aging of the National Institutes of Health under award number R41AG048723.
About NeurOp
NeurOp, Inc. is an Atlanta-based biopharmaceutical company developing new medicines for central nervous system disorders, including depression, neuropathic pain, ischemia (stroke), schizophrenia, and Alzheimer’s and Parkinson’s diseases. Its research targets various subunits of neuronal NMDA receptors and their potential therapeutic benefit. The company has licensed its technology to Bristol-Myers Squibb for the development of a compound for treatment-resistant depression. Funding from the NIH supports the company’s research and development programs for schizophrenia, Alzheimer’s disease and NP10679, its drug candidate for the prevention of ischemic damage during a stroke or subarachnoid hemorrhage. For more information, please visit www.neuropinc.com.
NeurOp contact:
Barney Koszalka, CEO
Phone: (919) 260-5595
Help employers find you! Check out all the jobs and post your resume.